CN118119599A - 阿昔替尼前药 - Google Patents

阿昔替尼前药 Download PDF

Info

Publication number
CN118119599A
CN118119599A CN202280066784.0A CN202280066784A CN118119599A CN 118119599 A CN118119599 A CN 118119599A CN 202280066784 A CN202280066784 A CN 202280066784A CN 118119599 A CN118119599 A CN 118119599A
Authority
CN
China
Prior art keywords
compound
oco
certain embodiments
och
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280066784.0A
Other languages
English (en)
Chinese (zh)
Inventor
P·贾勒特
R·艾尔-哈耶克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serpus Ophthalmology Co
Original Assignee
Serpus Ophthalmology Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serpus Ophthalmology Co filed Critical Serpus Ophthalmology Co
Publication of CN118119599A publication Critical patent/CN118119599A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280066784.0A 2021-10-15 2022-10-14 阿昔替尼前药 Pending CN118119599A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163255998P 2021-10-15 2021-10-15
US63/255,998 2021-10-15
PCT/US2022/046750 WO2023064578A1 (en) 2021-10-15 2022-10-14 Prodrugs of axitinib

Publications (1)

Publication Number Publication Date
CN118119599A true CN118119599A (zh) 2024-05-31

Family

ID=85987895

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280066784.0A Pending CN118119599A (zh) 2021-10-15 2022-10-14 阿昔替尼前药

Country Status (8)

Country Link
US (1) US20250092013A1 (cg-RX-API-DMAC7.html)
EP (1) EP4416132A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024537839A (cg-RX-API-DMAC7.html)
CN (1) CN118119599A (cg-RX-API-DMAC7.html)
AU (1) AU2022362310A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232086A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024003968A (cg-RX-API-DMAC7.html)
WO (1) WO2023064578A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119947722A (zh) * 2022-10-14 2025-05-06 视尔普斯眼科公司 前药、制剂及其方法
JP2026520094A (ja) 2023-04-11 2026-06-22 オキュラ セラピューティクス，インコーポレイテッド アキシチニブ多形ｉｖを含む眼科インプラント

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5721949B2 (ja) * 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
WO2016183296A1 (en) * 2015-05-12 2016-11-17 Incept, Llc Drug delivery from hydrogels
TWI664965B (zh) * 2015-06-22 2019-07-11 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法
CN106336397A (zh) * 2015-07-07 2017-01-18 郭明山 一种作为治疗眼科疾病的新化合物
WO2021035360A1 (en) * 2019-08-30 2021-03-04 Risen (Suzhou) Pharma Tech Co., Ltd. Prodrugs of the tyrosine kinase inhibitor for treating cancer
US12637441B2 (en) * 2019-08-30 2026-05-26 Risen (Suzhou) Pharma Tech Co., Ltd. Prodrugs of the tyrosine kinase inhibitor for treating cancer
CN112442010B (zh) * 2019-08-30 2023-10-03 润佳（苏州）医药科技有限公司 一类前药化合物及其在治疗癌症方面的应用
CA3171563A1 (en) * 2020-03-25 2021-09-30 Charles D. Blizzard Ocular implant containing a tyrosine kinase inhibitor

Also Published As

Publication number Publication date
MX2024003968A (es) 2024-04-29
EP4416132A4 (en) 2025-09-03
US20250092013A1 (en) 2025-03-20
EP4416132A1 (en) 2024-08-21
CA3232086A1 (en) 2023-04-20
WO2023064578A1 (en) 2023-04-20
JP2024537839A (ja) 2024-10-16
AU2022362310A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
JP2021046429A (ja) ハイドロゲル薬物送達インプラント
MXPA03008498A (es) Procesamiento en dos fases de polimeros termosensibles para uso como biomateriales.
CN113939271B (zh) 眼用水凝胶酪氨酸激酶抑制剂植入物
CN111481513A (zh) 缓释微球药物递送系统及其制备方法
WO2013155404A1 (en) Methods and compositions for preparing a silk microsphere
US20250092013A1 (en) Prodrugs of axitinib
JP2025513338A (ja) ｉｎ ｓｉｔｕで形成された共有結合を有する単一溶液ハイドロゲル、該ハイドロゲルを使用する組成物設計及び医療処置
WO2017015616A1 (en) Ocular protein delivery
EP3247406A1 (en) Compositions for the sustained release of anti-glaucoma agents to control intraocular pressure
CN119947722A (zh) 前药、制剂及其方法
US12453724B2 (en) Ocular implant containing a tyrosine kinase inhibitor
CN115501175A (zh) 一种用于多种药物递送的可生物降解水凝胶组合物及其制备方法和用途
US20250114373A1 (en) Intracanalicular insert comprising an antimicrobial agent
HK40115702A (en) Single solution hydrogels with covalent bonding formed in situ, composition design and medical procedures using the hydrogels
CN118742291A (zh) 包含非甾体抗炎剂的小管内插入物
CN118591369A (zh) 挤出式眼部插入物或植入物及其方法
HK40067669A (en) Ocular hydrogel tyrosine kinase inhibitor implants
Kurniawansyah et al. INTERNATIONAL RESEARCH JOURNAL OF PHARMACY

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination